Program
CKD-843
A development code. Also written as “CKD-843 dose#1”, “CKD-843 dose#2” and “CKD-843 A 45mg(Multiple dose)”.
Its studies are mostly in Alopecia, led by Chong Kun Dang Pharmaceutical.
Furthest: phase 3, since Apr 1, 20253 company-led studies, 1 open or runningNext primary completion: Sep 30, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chong Kun Dang Pharmaceutical | 31 open or running | phase 3since Apr 1, 2025 | Mar 16, 2021 | Sep 30, 2027phase 3 · NCT06916793 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 16, 2021First study: phase 1 study in AlopeciaFirst studyNCT04805606 · 40 enrolled · Korea, Republic of
- Oct 18, 2022Phase 1 study in AlopeciaNCT05587699 · 41 enrolled · Korea, Republic of
- Apr 1, 2025Phase 3 study in AlopeciaNCT06916793 · 288 planned · South Korea
Ahead
- Sep 30, 2027Primary completion: phase 3 study in AlopeciaNCT06916793
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06916793Alopecia · South Korea | 3 | Recruiting | Sep 30, 2027 | 288 |
| NCT05587699Alopecia · Korea, Republic of | 1 | Completed | Sep 15, 2023 | 41 |
| NCT04805606Alopecia · Korea, Republic of | 1 | Completed | Dec 24, 2021 | 40 |
How it is read
Names in the registry
- “CKD-843 dose#1”, 1 entry
- “CKD-843 dose#2”, 1 entry
- “CKD-843 A 45mg(Multiple dose)”, 1 entry
- “CKD-843 A 45mg”, 1 entry
- “CKD-843 A 55mg(Multiple dose)”, 1 entry
Codes read as this program: CKD843.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.